The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. (Q45901790)

17 December 2017

title

The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. (English)

1 reference

17 December 2017

1 reference

Kojiro Eto

1

1 reference

17 December 2017

Masaaki Iwatsuki

2

1 reference

17 December 2017

Masayuki Watanabe

3

1 reference

17 December 2017

Satoshi Ida

4

1 reference

17 December 2017

Takatsugu Ishimoto

5

1 reference

17 December 2017

Shiro Iwagami

6

1 reference

17 December 2017

Yoshifumi Baba

7

1 reference

17 December 2017

Yasuo Sakamoto

8

1 reference

17 December 2017

Yuji Miyamoto

9

1 reference

17 December 2017

Naoya Yoshida

10

1 reference

17 December 2017

Hideo Baba

11

1 reference

17 December 2017

publication date

24 October 2013

1 reference

17 December 2017

Annals of Surgical Oncology

published in

1 reference

17 December 2017

volume

21

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

343-350

1 reference

17 December 2017

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

microRNAs in cancer management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Oncomirs - microRNAs with a role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Catecholamine-Induced β2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

miR-21 plays a pivotal role in gastric cancer pathogenesis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3325-7

10.1245/S10434-013-3325-7

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

Dimensions Publication ID

1018331712

0 references

1 reference

17 December 2017